drugset / Trial / NCT06349733

A Dosage-dependent Manner of Botulinum Toxin Type A on the Prevention of Postoperative Scars of Various Anatomic Regions of the Body

NCT06349733

Phase 0 Completed 50 enrolled Qilu Hospital of Shandong University
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Each year, millions of burn, trauma, or surgical patients worldwide suffer from scarring that severely affects their quality of life and social functioning. In order to prevent and treat diseases related to abnormal scar hyperplasia, clinicians and researchers have adopted various methods, such as scar grinding, surgical resection, drug injection in scar tissue, cryotherapy, laser and so on. However, these methods can not effectively inhibit the abnormal proliferation of scars and improve the adverse effects of existing scars on patients. To date, there is no accepted gold standard for the effective treatment and improvement of abnormal scar tissue.

Timeline

Start
2023-03-23
Primary completion
2023-10-01
Completion
2024-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 1 iu Other
Subject Botulinum toxin type A Protein / enzyme biologic 2.5 iu Other
Subject Botulinum toxin type A Protein / enzyme biologic 5 iu Other

Indications

No indication recorded.